Compare Dyne Therapeutics Inc. Common Stock (DYN) vs iShares International Treasury Bond ETF (IGOV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dyne Therapeutics Inc. Common Stock vs iShares International Treasury Bond ETF — how do they compare? Dyne Therapeutics Inc. Common Stock trades at $15.06 (market cap $2.86B), while iShares International Treasury Bond ETF trades at $39.67 (market cap $1.31B). The key difference: Dyne Therapeutics Inc. Common Stock is far larger — about 2.2× iShares International Treasury Bond ETF's market cap, and iShares International Treasury Bond ETF is more actively traded (98,249 versus 3,341,579). Which is the better fit depends on your goals — on Pluang, investors hold Dyne Therapeutics Inc. Common Stock for 0 Days and iShares International Treasury Bond ETF for 92 Days on average.
| DYN | IGOV | |
|---|---|---|
Market Cap | $2.86B | $1.31B |
Volume | 3,341,579 | 98,249 |
Sector | Health | Fixed Income |
52-Week High | $26.78 | $42.99 |
52-Week Low | $14.60 | $39.58 |
Typical Hold Time | 0 Days | 92 Days |
Enterprise Value | $2.18B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dyne Therapeutics (DYN) trades at $15.30, down 4.14% on the day, reflecting recent volatility amid mixed clinical trial news. The stock is in a neutral technical position with immediate support at $15 and resistance at $16. Fundamentally, the company is a clinical-stage biotech with no revenue, reporting a net loss of $446.21M in 2025, but maintains strong analyst support with an 85.7% buy rating and a $35.20 consensus price target. Recent news highlights progress in Phase 1/2 trials for neuromuscular diseases and a $375M public offering in July 2026 to fund development.
The investment case hinges on clinical success, offering significant upside to the price target, but carries high risk due to pre-revenue status, dependence on trial outcomes, and negative cash flow from operations. Investor sentiment is cautiously optimistic, buoyed by analyst confidence, though volatility from sector-specific news remains a near-term challenge.
IGOV trades at $39.67, showing modest daily gains of 0.23% amid bearish technical signals. The stock faces selling pressure with moving averages indicating a downtrend, though oscillators suggest potential near-term momentum. Recent news highlights rising global bond yields creating headwinds for financial markets, while the company's key financial ratios remain undisclosed in current data.
The outlook remains cautious with technical indicators favoring bearish sentiment. Investment opportunities depend on improved fundamental metrics and market stabilization, while risks include persistent bond yield pressures and lack of clear profitability data. Stock investors should await clearer financial performance indicators before establishing positions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Dyne Therapeutics Inc. Common Stock
Dyne Therapeutics, Inc. is a clinical-stage biotechnology company developing therapeutics for genetically driven neuromuscular diseases, including Duchenne muscular dystrophy and myotonic dystrophy type 1, with additional preclinical programs for facioscapulohumeral muscular dystrophy and Pompe disease.
Read more on DYN →About iShares International Treasury Bond ETF
The fund will invest at least 80% of its assets in the component securities of the underlying index and will invest at least 90% of its assets in fixed income securities included in the underlying index. The underlying index measures the performance of fixed-rate, local currency, investment-grade, sovereign bonds from certain developed markets. The fund is non-diversified.
Read more on IGOV →
